DDInter1379 DDInter875
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Escitalopram
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sufentanil
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Palbociclib may lead to a major life threatening interaction when taken with Amprenavir
Palbociclib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated